Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck Ord Shs MKGAF

Alternate Symbol(s):  MKKGY

Healthcare
Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical... see more

Recent & Breaking News (OTCPK:MKGAF)

Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

PR Newswire Europe Non Regulatory February 15, 2018

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

PR Newswire February 15, 2018

The Consumer Health of Merck Walks the Talk with its WE100 Movement

PR Newswire Europe Non Regulatory January 18, 2018

FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

PR Newswire December 21, 2017

Merck Receives Approval (Updated Registration) for Mavenclad (Cladribine Tablets) in Australia

PR Newswire Europe Non Regulatory December 7, 2017

Merck KGaA, Darmstadt, Germany Announces FDA 510(k) Clearance of Partner Genea Biomedx’s Fertility Benchtop Incubator Geri™

PR Newswire December 5, 2017

Merck Announces FDA 510(k) Clearance of Partner Genea Biomedx's Fertility Benchtop Incubator Geri™

PR Newswire Europe Non Regulatory December 5, 2017

Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada

PR Newswire Europe Non Regulatory December 4, 2017

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer

PR Newswire November 28, 2017

Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer

PR Newswire November 28, 2017

Merck Receives FDA Approval for New GONAL-f® Prefilled Pen

PR Newswire Europe Non Regulatory November 13, 2017

Merck and International Diabetes Federation Partner to Help Address Global Type 2 Diabetes Epidemic

PR Newswire Europe Non Regulatory November 13, 2017

NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis

PR Newswire Europe Non Regulatory November 9, 2017

Merck's Consumer Health Leads Debate on Preparing Gen Z for 100 Healthy Years

Canada NewsWire November 7, 2017

Merck Announces Recipients of €1 Million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017

PR Newswire Europe Non Regulatory October 26, 2017

New Data at ECTRIMS Highlight Positive Benefit-Risk Profile of Mavenclad in Relapsing Multiple Sclerosis

PR Newswire Europe Non Regulatory October 26, 2017

New Report Launched at ECTRIMS 2017 Highlights Unique Impact of MS on Women in Europe

PR Newswire Europe Non Regulatory October 25, 2017

Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017

PR Newswire Europe Non Regulatory October 18, 2017

Merck Invests € 35 Million in its Italian Biotech Manufacturing Site of Bari

PR Newswire Europe Non Regulatory October 3, 2017

European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma

PR Newswire September 21, 2017